Olivier Godefroy1, Olivier Martinaud2, Marc Verny3, Chrystèle Mosca4, Hermine Lenoir5, Eric Bretault6, Martine Roussel1. 1. Department of Neurology, Laboratory of Functional Neurosciences, University Hospital of Amiens, France. 2. Department of Neurology, Rouen University Hospital, France. 3. Geriatric Center, CMRR, Pitié-Salpêtrière University Hospital (AP-HP and UPMC), Paris, France. 4. Department of Neurology, CMRR, University Hospital of Grenoble, France. 5. Department of Gerontology, Broca Hospital, AP HP, Paris Descartes University, Paris, France. 6. Department of Neurology, General Hospital of Cholet, France.
Abstract
BACKGROUND: Dysexecutive disorders are common in early-stage Alzheimer's disease (AD) but have yet to be characterized in detail. OBJECTIVE: The objectives of the present study based on validated diagnostic criteria were to determine the frequency and characterize the profile of behavioral and cognitive dysexecutive disorders in AD. METHODS: 102 patients with AD (mild: n = 92; moderate: n = 10; mean MMSE score: 23.2) were examined with the GREFEX battery. Neuropsychological data were interpreted within a validated framework based on the performance levels of 780 control participants from the GREFEX study. RESULTS: Dysexecutive syndrome was observed in 87.5% (95%CI: 79-96) of the AD patients (p = 0.0001). The dysexecutive disorder profile was characterized by prominent impairments of planning, inhibition flexibility and generation in the cognitive domain (p = 0.0001 as compared to controls for all) and global hypoactivity in the behavioral domain (p = 0.0001 as compared to controls). CONCLUSIONS: Dysexecutive syndrome is observed in over 80% of AD patients and has a distinct profile.
BACKGROUND:Dysexecutive disorders are common in early-stage Alzheimer's disease (AD) but have yet to be characterized in detail. OBJECTIVE: The objectives of the present study based on validated diagnostic criteria were to determine the frequency and characterize the profile of behavioral and cognitive dysexecutive disorders in AD. METHODS: 102 patients with AD (mild: n = 92; moderate: n = 10; mean MMSE score: 23.2) were examined with the GREFEX battery. Neuropsychological data were interpreted within a validated framework based on the performance levels of 780 control participants from the GREFEX study. RESULTS:Dysexecutive syndrome was observed in 87.5% (95%CI: 79-96) of the ADpatients (p = 0.0001). The dysexecutive disorder profile was characterized by prominent impairments of planning, inhibition flexibility and generation in the cognitive domain (p = 0.0001 as compared to controls for all) and global hypoactivity in the behavioral domain (p = 0.0001 as compared to controls). CONCLUSIONS:Dysexecutive syndrome is observed in over 80% of ADpatients and has a distinct profile.
Authors: Brandon Frank; Madeline Ally; Yorghos Tripodis; Christian Puzo; Caroline Labriolo; Landon Hurley; Brett Martin; Joseph Palmisano; Lawrence Chan; Eric Steinberg; Katherine Turk; Andrew Budson; Maureen O'Connor; Rhoda Au; Wei Qiao Qiu; Lee Goldstein; Walter Kukull; Neil Kowall; Ronald Killiany; Robert Stern; Thor Stein; Ann McKee; Jesse Mez; Michael Alosco Journal: Neurology Date: 2022-04-20 Impact factor: 11.800
Authors: Daniel Ferreira; Farshad Falahati; Cecilia Linden; Rachel F Buckley; Kathryn A Ellis; Greg Savage; Victor L Villemagne; Christopher C Rowe; David Ames; Andrew Simmons; Eric Westman Journal: Sci Rep Date: 2017-03-13 Impact factor: 4.379
Authors: Lyndsey M Miller; Diane N Solomon; Carol J Whitlatch; Shirin O Hiatt; Chao-Yi Wu; Christina Reynolds; Wan-Tai Michael Au-Yeung; Jeffrey Kaye; Joel S Steele Journal: Innov Aging Date: 2022-02-07
Authors: E Blanco Martín; I Ugarriza Serrano; X Elcoroaristizabal Martín; L Galdos Alcelay; A Molano Salazar; R Bereincua Gandarias; S Inglés Borda; J M Uterga Valiente; M B Indakoetxea Juanbeltz; J Moraza Lopez; M Barandiarán Amillano; M Fernández-Martínez Journal: BMC Neurol Date: 2016-06-04 Impact factor: 2.474